The Research Network (TRN) is excited to announce that a new Therapeutic Team has joined the network – the Cardiovascular and Metabolic Disease Team.
The Cardiovascular and Metabolic Disease group evolved from scientists of the AstraZeneca Alderley Park, UK and Pfizer US sites. Through us you have immediate access to over 200 years of successful metabolic disease drug discovery and development expertise in the fields of medicinal chemistry, biochemistry, molecular biology, in vitro and in vivo pharmacology, physiology, small molecule, peptide and protein science.
We joined TRN not only to broaden the knowledge and expertise that we, and TRN, can offer but also to provide our clients the benefits of simpler and cheaper access to the best CRO partners.
We can help you undertake due diligence, in-licensing opportunity evaluation and help focus your efforts developing metabolic disease projects and strategy and help you make the right decisions at the right time.